Gothenburg, Sweden

Elisabeth Odin

USPTO Granted Patents = 4 

 

 

Average Co-Inventor Count = 3.6

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Göteborg, SE (2019)
  • Gothenburg, SE (2019 - 2022)

Company Filing History:


Years Active: 2019-2022

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Elisabeth Odin: Innovator in Thymidylate Synthase Inhibition

Introduction

Elisabeth Odin is a prominent inventor based in Gothenburg, Sweden. She has made significant contributions to the field of medical research, particularly in the area of blood plasma and thymidylate synthase inhibition. With a total of four patents to her name, her work is paving the way for advancements in therapeutic methods.

Latest Patents

Elisabeth's latest patents focus on methods for increasing blood plasma 2'-deoxyuridine (dUrd) and thymidylate synthase inhibition. The present invention provides methods for increasing plasma dUrd levels through the administration of 6R-MTHF. These methods effectively increase dUrd levels compared to equimolar concentrations of LV. Additionally, her inventions also include methods for enhancing TS inhibition, again utilizing the administration of 6R-MTHF.

Career Highlights

Elisabeth Odin is currently associated with Isofol Medical AB, where she continues to innovate and develop her research. Her work has garnered attention in the medical community, contributing to the understanding of dUrd levels and their implications in treatment methodologies.

Collaborations

Elisabeth collaborates with notable colleagues such as Yvonne Wettergren and Göran U Carlsson. Their combined expertise enhances the research and development efforts at Isofol Medical AB.

Conclusion

Elisabeth Odin's contributions to medical research through her patents and collaborations highlight her role as a leading inventor in the field. Her innovative methods for increasing blood plasma dUrd levels and thymidylate synthase inhibition are set to make a significant impact in therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…